Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home

Shape Biopharmaceuticals

SME

shapebiopharma.comAu ZH, Switzerland
29 profile visits

About

Shape Biopharmaceuticals AG develops multi-target antibody-inducing immunotherapies using its fully synthetic SHAPEnano nanoparticle platform. The technology enables durable modulation of multiple pathways with ultra-low dosing and scalable peptide-like manufacturing. Our lead program targets PCSK9 and ANGPTL pathways for mixed hyperlipidemia, with in vivo proof-of-concept showing combined cholesterol and triglyceride lowering. We are advancing toward clinical candidate nomination and seek partners for R&D, EU projects, and translational development.

What is your business/industry sector?

Biotech, Pharma and CosmeticsHealthcare

Representatives

Arin Ghasparian

Co-founder & CEO

Shape Biopharmaceuticals

Armando Zuniga

CSO

Shape Biopharmaceuticals

Marketplace (1)

  • Project cooperation

    Antibody inducing Immunotherapies

    At Shape we develop programmable antibody inducing nanoparticle immunotherapies for cardiometabolic and other diseases. Looking for cooperations to further develop our platform and explore novel targets in cardiometabolic, I&I and immuno-oncoly areas.

    • Early
    • Planning
    • Healthcare
    • EU projects
    Author

    Arin Ghasparian

    Co-founder & CEO at Shape Biopharmaceuticals

    Au ZH, Switzerland